GPX4 and melanoma: GSH and redox homeostasis have been widely demonstrated to play a crucial role in therapy-resistance (18, 65–67) and it has been recently reported that compounds able to inhibit GSH peroxidase 4 (GPX4) induce ferroptosis in BRAFV600E mutant melanoma cells increasing the sensitivity to Vemurafenib (68).